Cancer

Vanderbilt’s Robert Coffey Jr., M.D., has received an Outstanding Investigator Award from the National Cancer Institute (NCI) — more than $6.6 million over seven years — to support studies aimed at advancing the diagnosis and treatment of colorectal cancer (CRC), a leading cancer killer.

An international genomic data-sharing consortium has analyzed nearly 19,000 patient genomic records and found that testing of patient tumors for relevant gene mutations often provides a roadmap for the use of effective therapies.

Vanderbilt-Ingram Cancer Center (VICC), in collaboration with the Hereditary Cancer Program and the Vanderbilt Breast Center, is hosting a free seminar, “Are You at High Risk for Breast Cancer?”

In 2012, the United States Preventive Services Task Force recommended that men of all ages should not be routinely screened for levels of prostate-specific antigen (PSA). That group now recommends that men ages 55 to 69 should talk with their doctors and make well-informed individual decisions about the potential harms and benefits of PSA screening, and treatment if cancer is found.

Blood type A was associated with longer ovarian cancer survival in a recent Vanderbilt-led study.

Vanderbilt University Medical Center cancer researcher James Goldenring, M.D., Ph.D., has received a two-year, $200,000 grant from the DeGregorio Family Foundation in Pleasantville, New York, to begin clinical trials of a potential approach for reversing precancerous stomach lesions.

In 2012, the United States Preventive Services Task Force recommended that men of all ages should not be routinely screened for levels of prostate-specific antigen (PSA). These are the blood tests to detect the possibility of prostate cancer.